Tags

Liquid chromatography coupled to mass spectrometry: separation and identification in one run, and the method of choice when you need to know not just how much…

Regain after stopping or reducing: the trajectory reported in the withdrawal extensions, how much is fluid, and what the maintenance arms tell us about…

Polycystic ovary syndrome: insulin resistance as the shared mechanism, ovulatory and menstrual outcomes reported on treatment, androgen changes, and…

Kidney endpoints: the FLOW composite, eGFR slope as an endpoint, albuminuria regression, and why an early eGFR dip is expected rather than alarming.

A fixed-ratio combination of cagrilintide, a long-acting amylin analogue, with semaglutide, studied in the REDEFINE programme. Questions here concern the…

Glucagon receptor agonism as a deliberate component of dual and tri-agonists: what it adds in energy expenditure and hepatic fat mobilisation, and what it…

Cholelithiasis and cholecystitis risk during rapid weight loss and on treatment: how much is attributable to the rate of loss versus to the drug, and what the…

The reduction in intrusive, appetitive thinking about food that most people on the class describe. Its likely basis in central GLP-1R signalling, why it is…

Clinically meaningful loss of muscle mass and function, particularly in older adults on treatment. Distinguishing a proportional reduction from a functional…

Obstructive sleep apnoea and the apnoea-hypopnoea index response to weight loss, including the SURMOUNT-OSA dataset and the question of whether treatment can…

Remote prescribing: what a defensible intake looks like, asynchronous-visit rules, subscription models that bundle a compounded product, and transferring care…